NewTimeSpace: CK Life Sciences Int'l., (Holdings) Inc. (00775.HK) announced the establishment of Sequencio (Shunpu Pharmaceutical Technology Co., Ltd.), a wholly-owned subsidiary dedicated to the development of its portfolio of therapeutic cancer vaccines.Sequencio’s preclinical pipeline includes vaccine candidates targeting TROP2, PRAME, PD-L1, B7-H3 and Claudin 6. Among them, the TROP2-targeted vaccine demonstrated complete tumor growth inhibition in preclinical studies.
NewTimeSpace News,On March 9, Addvalue Technologies Ltd announced via a regulatory filing that the Group has secured new orders worth approximately US$3.7 million through its core growth business – space connectivity-related operations, covering multiple Inter-Satellite Data Relay System (IDRS) terminals. The delivery of these orders is expected to be substantially completed within the next 12 months.
NewTimeSpace News,According to an announcement released by the Singapore Exchange on March 5, Wipro, an India-based AI-driven technology services and consulting company, announced the appointment of Ms. Laura Marie Miller as a director of the company. Her five-year term will take effect on April 1, 2026, subject to shareholder approval.
On March 5, Ligent Technologies resubmitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Citigroup Global Markets Asia Limited and CITIC Securities (Hong Kong) as joint sponsors. As a leading global supplier of optical communication and optical connectivity products, the company specializes in the R&D, manufacturing and sales of optical modules, optical chips and optical network terminals.
NewTimeSpace:SSY Group Limited (02005.HK) announced that it has obtained the drug production registration approval from the National Medical Products Administration (NMPA) for Calcium Levofolinate for Injection (25mg). The product is classified as a Class 3 chemical drug and is deemed to have passed the consistency evaluation. It is mainly used for the treatment of gastric cancer and colorectal cancer.
NewTimeSpace: Shanghai Henlius Biotech, Inc. (02696.HK) announced a voluntary announcement that the Phase 1 clinical trial application of HLX97, a self-developed KAT6A/B small-molecule inhibitor, for the treatment of advanced/metastatic solid tumors has been approved by the National Medical Products Administration (NMPA) of China. As of the date of this announcement, no similar products have been approved for marketing worldwide.
NewTimeSpace News,On 4 March, Singapore-listed ATLANTIC NAVIGATION HLDG(S)LTD announced that Saeed Investment acquired 130 million shares of the company on 3 March, raising its deemed interest in the company from 50.2% to 75.1%.
As the "first Data Agent stock on the HKEX," Xunce (03317.HK) has demonstrated strong share price performance since its listing at the end of 2025. As of March 3, 2026, the closing price was HK$77.45, up 61.35% from the offer price, and it was included in the Hang Seng Composite Index in just 45 days. However, the enthusiasm in the secondary market cannot hide its fundamental pressures. Core financial and operational warnings: revenue in the first half of 2025 decreased by 30% year-on-year, and the loss for the period expanded to RMB 108 million. R&D expenses remain high, consistently accounting for over 70% of revenue.
NewTimeSpace News,According to a disclosure from the Singapore Exchange on March 2, SOFTBANK GROUP CORP. announced that it had entered into a definitive agreement with OpenAI Group on February 27 (U.S. time) to make an additional investment of $30 billion through SoftBank Vision Fund 2. Upon the completion of this investment,SOFTBANK GROUP CORP.’s cumulative investment in OpenAI will amount to $64.6 billion, representing an approximate 13% shareholding in the company.
NewTimeSpace News,On March 2, Singapore-listed company ATLANTIC NAVIGATION HLDG(S)LTD released an announcement updating on the escalating conflict situation in the Middle East since February 28, clarifying that its offshore marine logistics business, primarily operated in the Arabian Gulf, has not suffered any material disruptions, with no casualties among its employees and crew nor losses to relevant assets.
NewTimeSpace News: Shenzhen Zhaowei Machinery & Electronics Co., Ltd. (02692.HK) officially launched its H‑share global offering on February 27, 2026. As China’s largest provider of integrated micro‑transmission and drive systems, Zhaowei has built strong barriers in high‑end manufacturing sectors such as smart vehicles, consumer tech, and medical technology through its “1+1+1” collaborative innovation system integrating transmission, micro‑motor, and electronic control systems.
Shanghai W-Ibeda High Tech Group Co., Ltd. filed for listing on the Hong Kong Stock Exchange on February 24. As a leading Chinese provider of new energy vehicle powertrain testing solutions, the company operates three business segments: testing services, intelligent driving, and testing equipment. Financial results show sustained revenue growth, while profitability is under short-term pressure due to upfront costs from capacity expansion.
Hangzhou GreenCloud Software Co., Ltd. files for HK IPO backed by Ctrip, serving 37,000 hotels with 16.8% PMS market share. Only profitable player among top 5 peers, yet faces supplier concentration risk. Funds target AI hotel OS R&D.
On February 10, 2026, Shenzhen Zeroth AI Technology Co., Ltd., an AI company founded just over five years ago, formally submitted its listing application to the Hong Kong Stock Exchange, with CMBC Capital as the exclusive sponsor. According to Frost & Sullivan, by revenue in 2024, Zeroth AI has become the fifth-largest provider of enterprise-grade AI agent solutions in China, with a market share of 3.0%. Centered on its self-developed “BlackZero” platform and focused on AI assistants for contract and investment scenarios, the young company has stepped into the capital market with its net profit tripled over three years.
February 11, 2026, NETEASE MUSIC(09899.HK) released its Annual Report for the period ended December 31, 2025, Total Revenue stood at CNY 7.76 billion, decreased by 2.4% YoY
NewTimeSpace News, according to an announcement disclosed on the Singapore Exchange on February 10, Japan's Takeda Pharmaceutical announced that its New Drug Application (NDA) for Oveporexton (TAK-861), a potential first-in-class therapy developed by the company, has been accepted by the U.S. Food and Drug Administration (FDA) and granted priority review status for the treatment of Narcolepsy Type 1 (NT1).
